Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)

Tipranks - Tipranks - Wed Apr 15, 8:38PM CDT

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on April 13 and set a price target of CHF135.00. The company’s shares closed yesterday at CHF120.62.

Claim 30% Off TipRanks

According to TipRanks, Evans is ranked #6721 out of 12125 analysts.

Novartis AG has an analyst consensus of Moderate Buy, with a price target consensus of CHF121.92, which is a 1.08% upside from current levels. In a report released on April 13, Citi also maintained a Buy rating on the stock with a $0.00 price target.

See the top stocks recommended by analysts >>

Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).